MannKind’s Future Uncertain After Sanofi Terminates Afrezza Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
During a very brief investor call, MannKind says it is planning to change its pricing and contracting tactics, after being left in the lurch as Sanofi terminates its development and commercialization deal on the inhaled insulin Afrezza.
You may also be interested in...
Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk
FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.